[1] S. Stuver, D. Trichopoulos, H.O. Adami, D. Hunter, and D. Trichopoulos, Cancer of the liver and biliary tract. (2008).
[2] F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, and A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 68 (2018) 394-424.
[3] K. Popat, K. Mcqueen, and T.W.J.B.P.R.C.A. Feeley, The global burden of cancer. 27 (2013) 399-408.
[4] M. Minagawa, I. Ikai, Y. Matsuyama, Y. Yamaoka, and M. Makuuchi, Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Annals of surgery 245 (2007) 909-22.
[5] J.U. Marquardt, P.R. Galle, and A. Teufel, Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. Journal of hepatology 56 (2012) 267-75.
[6] T. Couri, and A. Pillai, Goals and targets for personalized therapy for HCC. Hepatology international 13 (2019) 125-137.
[7] T. El Jabbour, S.M. Lagana, and H. Lee, Update on hepatocellular carcinoma: Pathologists' review. World journal of gastroenterology 25 (2019) 1653-1665.
[8] N.C. Andrews, Disorders of iron metabolism. The New England journal of medicine 341 (1999) 1986-95.
[9] N.C. Andrews, Forging a field: the golden age of iron biology. Blood 112 (2008) 219-30.
[10] D.H. Manz, N.L. Blanchette, B.T. Paul, F.M. Torti, and S.V. Torti, Iron and cancer: recent insights. Annals of the New York Academy of Sciences 1368 (2016) 149-61.
[11] L. Zhou, B. Zhao, L. Zhang, S. Wang, D. Dong, H. Lv, and P. Shang, Alterations in Cellular Iron Metabolism Provide More Therapeutic Opportunities for Cancer. International journal of molecular sciences 19 (2018).
[12] M.K. Ali, R.Y. Kim, R. Karim, J.R. Mayall, K.L. Martin, A. Shahandeh, F. Abbasian, M.R. Starkey, V. Loustaud-Ratti, D. Johnstone, E.A. Milward, P.M. Hansbro, and J.C. Horvat, Role of iron in the pathogenesis of respiratory disease. The international journal of biochemistry & cell biology 88 (2017) 181-195.
[13] A. Fonseca-Nunes, P. Jakszyn, and A. Agudo, Iron and cancer risk--a systematic review and meta-analysis of the epidemiological evidence. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 23 (2014) 12-31.
[14] Y. Chen, Z. Fan, Y. Yang, and C. Gu, Iron metabolism and its contribution to cancer (Review). International journal of oncology 54 (2019) 1143-1154.
[15] B.R. Stockwell, J.P. Friedmann Angeli, H. Bayir, A.I. Bush, M. Conrad, S.J. Dixon, S. Fulda, S. Gascon, S.K. Hatzios, V.E. Kagan, K. Noel, X. Jiang, A. Linkermann, M.E. Murphy, M. Overholtzer, A. Oyagi, G.C. Pagnussat, J. Park, Q. Ran, C.S. Rosenfeld, K. Salnikow, D. Tang, F.M. Torti, S.V. Torti, S. Toyokuni, K.A. Woerpel, and D.D. Zhang, Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell 171 (2017) 273-285.
[16] E. Ooko, M.E. Saeed, O. Kadioglu, S. Sarvi, M. Colak, K. Elmasaoudi, R. Janah, H.J. Greten, and T. Efferth, Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. Phytomedicine : international journal of phytotherapy and phytopharmacology 22 (2015) 1045-54.
[17] H. Yamaguchi, J.L. Hsu, C.T. Chen, Y.N. Wang, M.C. Hsu, S.S. Chang, Y. Du, H.W. Ko, R. Herbst, and M.C. Hung, Caspase-independent cell death is involved in the negative effect of EGF receptor inhibitors on cisplatin in non-small cell lung cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research 19 (2013) 845-54.
[18] A. Houessinon, C. Francois, C. Sauzay, C. Louandre, G. Mongelard, C. Godin, S. Bodeau, S. Takahashi, Z. Saidak, L. Gutierrez, J.M. Regimbeau, N. Barget, J.C. Barbare, N. Ganne, B. Chauffert, R. Coriat, and A. Galmiche, Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib. Molecular cancer 15 (2016) 38.
[19] J. Nie, B. Lin, M. Zhou, L. Wu, and T. Zheng, Role of ferroptosis in hepatocellular carcinoma. Journal of cancer research and clinical oncology 144 (2018) 2329-2337.
[20] L.B. Alexandrov, S. Nik-Zainal, D.C. Wedge, S.A. Aparicio, S. Behjati, A.V. Biankin, G.R. Bignell, N. Bolli, A. Borg, A.L. Borresen-Dale, S. Boyault, B. Burkhardt, A.P. Butler, C. Caldas, H.R. Davies, C. Desmedt, R. Eils, J.E. Eyfjord, J.A. Foekens, M. Greaves, F. Hosoda, B. Hutter, T. Ilicic, S. Imbeaud, M. Imielinski, N. Jager, D.T. Jones, D. Jones, S. Knappskog, M. Kool, S.R. Lakhani, C. Lopez-Otin, S. Martin, N.C. Munshi, H. Nakamura, P.A. Northcott, M. Pajic, E. Papaemmanuil, A. Paradiso, J.V. Pearson, X.S. Puente, K. Raine, M. Ramakrishna, A.L. Richardson, J. Richter, P. Rosenstiel, M. Schlesner, T.N. Schumacher, P.N. Span, J.W. Teague, Y. Totoki, A.N. Tutt, R. Valdes-Mas, M.M. van Buuren, L. van 't Veer, A. Vincent-Salomon, N. Waddell, L.R. Yates, J. Zucman-Rossi, P.A. Futreal, U. McDermott, P. Lichter, M. Meyerson, S.M. Grimmond, R. Siebert, E. Campo, T. Shibata, S.M. Pfister, P.J. Campbell, and M.R. Stratton, Signatures of mutational processes in human cancer. Nature 500 (2013) 415-21.
[21] Ton N., Schumacher, Can, Kesmir, Marit M., and van Buuren, Biomarkers in Cancer Immunotherapy.
[22] Z.R. Chalmers, C.F. Connelly, D. Fabrizio, L. Gay, S.M. Ali, R. Ennis, A. Schrock, B. Campbell, A. Shlien, J. Chmielecki, F. Huang, Y. He, J. Sun, U. Tabori, M. Kennedy, D.S. Lieber, S. Roels, J. White, G.A. Otto, J.S. Ross, L. Garraway, V.A. Miller, P.J. Stephens, and G.M. Frampton, Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome medicine 9 (2017) 34.
[23] E.M. Van Allen, N. Wagle, P. Stojanov, D.L. Perrin, K. Cibulskis, S. Marlow, J. Jane-Valbuena, D.C. Friedrich, G. Kryukov, S.L. Carter, A. McKenna, A. Sivachenko, M. Rosenberg, A. Kiezun, D. Voet, M. Lawrence, L.T. Lichtenstein, J.G. Gentry, F.W. Huang, J. Fostel, D. Farlow, D. Barbie, L. Gandhi, E.S. Lander, S.W. Gray, S. Joffe, P. Janne, J. Garber, L. MacConaill, N. Lindeman, B. Rollins, P. Kantoff, S.A. Fisher, S. Gabriel, G. Getz, and L.A. Garraway, Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nature medicine 20 (2014) 682-8.
[24] W. Wang, M. Green, J.E. Choi, M. Gijón, P.D. Kennedy, J.K. Johnson, P. Liao, X. Lang, I. Kryczek, and A.J.N. Sell, CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy.
[25] S. Zhang, W. Chang, H. Wu, Y.-H. Wang, Y.-W. Gong, Y.-L. Zhao, L. Shanhui, H.-Z. Wang, R. Svatek, R. Rodriguez, and Z.-P. Wang, Pan-cancer analysis of iron metabolic landscape across the Cancer Genome Atlas: ZHANG et al. Journal of Cellular Physiology 235 (2019).
[26] E. Becht, N.A. Giraldo, L. Lacroix, B. Buttard, N. Elarouci, F. Petitprez, J. Selves, P. Laurent-Puig, C. Sautes-Fridman, W.H. Fridman, and A. de Reynies, Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome biology 17 (2016) 218.
[27] T. Park, and G.J.P.o.t.A.S.A. Casella, The Bayesian Lasso. 103 681-686.
[28] A.J. Vickers, A.M. Cronin, E.B. Elkin, and M. Gonen, Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. 8 53-0.
[29] Characterization of small nodules in cirrhosis by assessment of vascularity: The problem of hypovascular hepatocellular carcinoma %J Hepatology. 42 (2005).
[30] S.L. Topalian, Targeting Immune Checkpoints in Cancer Therapy. Jama 318 (2017) 1647-1648.
[31] T.A. Chan, M. Yarchoan, E. Jaffee, C. Swanton, S.A. Quezada, A. Stenzinger, and S. Peters, Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Annals of oncology : official journal of the European Society for Medical Oncology 30 (2019) 44-56.
[32] Y. Shibata, H. Yasui, K. Higashikawa, N. Miyamoto, and Y. Kuge, Erastin, a ferroptosis-inducing agent, sensitized cancer cells to X-ray irradiation via glutathione starvation in vitro and in vivo. PloS one 14 (2019) e0225931.
[33] K. Sartorius, B. Sartorius, C. Aldous, P.S. Govender, and T.E. Madiba, Global and country underestimation of hepatocellular carcinoma (HCC) in 2012 and its implications. Cancer epidemiology 39 (2015) 284-90.
[34] G. Garcia-Tsao, and J.K. Lim, Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. The American journal of gastroenterology 104 (2009) 1802-29.
[35] A. Forner, J.M. Llovet, and J. Bruix, Hepatocellular carcinoma. 10 (2006) 339-351.
[36] T. Reck, F. K?ckerling, A. Altendorf-Hofmann, P. Haller-Pittrow, C. Wittekind, and W.J.E.J.o.C. Hohenberger, Liver resection and liver transplantation for primary hepatocellular carcinoma. 33 S278.
[37] B. Njei, Y. Rotman, I. Ditah, and J.K. Lim, Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology (Baltimore, Md.) 61 (2015) 191-9.
[38] D.J. Erstad, B.C. Fuchs, and K.K. Tanabe, Molecular signatures in hepatocellular carcinoma: A step toward rationally designed cancer therapy. Cancer 124 (2018) 3084-3104.
[39] M. Nakamura, T. Chiba, K. Kanayama, H. Kanzaki, T. Saito, Y. Kusakabe, and N. Kato, Epigenetic dysregulation in hepatocellular carcinoma: an up-to-date review. Hepatology research : the official journal of the Japan Society of Hepatology 49 (2019) 3-13.
[40] M. Gao, P. Monian, Q. Pan, W. Zhang, J. Xiang, and X. Jiang, Ferroptosis is an autophagic cell death process. Cell research 26 (2016) 1021-32.
[41] A.R. Bogdan, M. Miyazawa, K. Hashimoto, and Y. Tsuji, Regulators of Iron Homeostasis: New Players in Metabolism, Cell Death, and Disease. Trends in biochemical sciences 41 (2016) 274-286.
[42] H. Yu, P. Guo, X. Xie, Y. Wang, and G. Chen, Ferroptosis, a new form of cell death, and its relationships with tumourous diseases. Journal of cellular and molecular medicine 21 (2017) 648-657.
[43] C. Louandre, Z. Ezzoukhry, C. Godin, J.C. Barbare, J.C. Maziere, B. Chauffert, and A. Galmiche, Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. International journal of cancer 133 (2013) 1732-42.
[44] X. Sun, Z. Ou, R. Chen, X. Niu, D. Chen, R. Kang, and D. Tang, Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology (Baltimore, Md.) 63 (2016) 173-84.
[45] R.C. Boswell-Casteel, Y. Fukuda, and J.D. Schuetz, ABCB6, an ABC Transporter Impacting Drug Response and Disease. The AAPS journal 20 (2017) 8.
[46] R. Tsunedomi, N. Iizuka, K. Yoshimura, M. Iida, M. Tsutsui, N. Hashimoto, S. Kanekiyo, K. Sakamoto, T. Tamesa, and M. Oka, ABCB6 mRNA and DNA methylation levels serve as useful biomarkers for prediction of early intrahepatic recurrence of hepatitis C virus-related hepatocellular carcinoma. International journal of oncology 42 (2013) 1551-9.
[47] D. Chiabrando, M. Castori, M. di Rocco, M. Ungelenk, S. Giesselmann, M. Di Capua, A. Madeo, P. Grammatico, S. Bartsch, C.A. Hubner, F. Altruda, L. Silengo, E. Tolosano, and I. Kurth, Mutations in the Heme Exporter FLVCR1 Cause Sensory Neurodegeneration with Loss of Pain Perception. PLoS genetics 12 (2016) e1006461.
[48] Y. Shen, X. Li, B. Zhao, Y. Xue, S. Wang, X. Chen, J. Yang, H. Lv, and P. Shang, Iron metabolism gene expression and prognostic features of hepatocellular carcinoma. Journal of cellular biochemistry 119 (2018) 9178-9204.
[49] A.A. Khan, and J.G. Quigley, Heme and FLVCR-related transporter families SLC48 and SLC49. Molecular aspects of medicine 34 (2013) 669-82.
[50] T. Liu, L. Jiang, O. Tavana, and W. Gu, The Deubiquitylase OTUB1 Mediates Ferroptosis via Stabilization of SLC7A11. Cancer research 79 (2019) 1913-1924.
[51] X. Lang, M.D. Green, W. Wang, J. Yu, J.E. Choi, L. Jiang, P. Liao, J. Zhou, Q. Zhang, A. Dow, A.L. Saripalli, I. Kryczek, S. Wei, W. Szeliga, L. Vatan, E.M. Stone, G. Georgiou, M. Cieslik, D.R. Wahl, M.A. Morgan, A.M. Chinnaiyan, T.S. Lawrence, and W. Zou, Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11. Cancer discovery 9 (2019) 1673-1685.
[52] C. Yue, Y. Ren, H. Ge, C. Liang, Y. Xu, G. Li, J.J.O. Wu, and Therapy, Comprehensive analysis of potential prognostic genes for the construction of a competing endogenous RNA regulatory network in hepatocellular carcinoma. Volume 12 561-576.
[53] G. Abril-Rodriguez, and A. Ribas, SnapShot: Immune Checkpoint Inhibitors. Cancer cell 31 (2017) 848-848.e1.
[54] G.P. Dunn, A.T. Bruce, H. Ikeda, L.J. Old, and R.D.J.N.I. Schreiber, Cancer immunoediting: from immunosurveillance to tumor escape. 3 991-998.
[55] Pardoll, and D. M., The blockade of immune checkpoints in cancer immunotherapy. 12 252-264.
[56] F. Galuppini, C.A.D. Pozzo, J. Deckert, F. Loupakis, and R.B.J.C.C. International, Tumor mutation burden: from comprehensive mutational screening to the clinic. 19 (2019).
[57] S.J. Dixon, K.M. Lemberg, M.R. Lamprecht, R. Skouta, E.M. Zaitsev, C.E. Gleason, D.N. Patel, A.J. Bauer, A.M. Cantley, and W.S. Yang, Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death. 149.
[58] S.J. Dixon, P.D. N, W. Matthew, S. Rachid, L.E. D, H. Miki, T.A. G, G.C. E, T.N. P, and S.B.S.J. eLife, Pharmacological inhibition of cystine–glutamate exchange induces endoplasmic reticulum stress and ferroptosis. 3.
[59] Veldhoen, and M.J.N. Immunology, Interleukin 17 is a chief orchestrator of immunity. 18 612-621.